PerkinElmer named as exclusive distributor of InSphero state-of-the-art 3D culture technology.
Schlieren, Switzerland (PRWEB) August 05, 2015
InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, announced today that its patented GravityPLUS™ Hanging Drop System and new GravityTRAP™ Ultra-Low Attachment (ULA) Plates are now available for purchase exclusively through PerkinElmer.
InSphero will now broaden global access to its 3D cell culture plates, while simplifying ordering and delivery logistics for a worldwide customer base. Working with PerkinElmer, InSphero will be better able to meet increasing demand for reliable methods to grow cells as more biologically relevant 3D spheroids. Furthermore, this agreement will provide additional capabilities to PerkinElmer’s extensive portfolio of consumables, assays, and imaging systems, which the two companies have used to develop novel assays for drug discovery, safety, and efficacy testing.
“The agreement immediately accelerates our ability to efficiently supply and deliver InSphero plate technologies internationally, and also forges a strategic relationship for the continued development of next-generation 3D cell culture platforms, as well as 3D-optimized imaging and cell-based assay protocols,” says Dr. Jan Lichtenberg, CEO and co-founder of InSphero.
Lichtenberg notes that the relationship between the two companies has already yielded novel, high content imaging applications for assessing compound toxicity in liver microtissues, and enabled users to perform RNA interference screens to sensitize tumor spheroids to radiation in research applications.
“Our customers will benefit from PerkinElmer’s global reach and technical expertise in experimental workflows when ordering and using InSphero plates. Our reliable, automation-compatible 3D cell culture platforms complement PerkinElmer’s assays and high-content imaging systems,” said Dr. Lichtenberg.
InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company’s patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero’s technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.
Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.
For the original version on PRWeb visit: http://www.prweb.com/releases/2015/08/prweb12885917.htm